treatment

Menin Inhibitor

<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-626" src="http://cms.syndax.com/wp-content/uploads/2023/11/Uckelmann_Revumenib_ASH2018-12.png" alt="" width="1069" height="430" /></p>
<p><em>Source: *KMT2A = KMT2A rearrangement or KMT2A wildtype; Adapted from: Uckelmann HJ, et al. Presented at ASH Annual Meeting, 2018.</em></p>
<p>Menin is a scaffold protein, and its binding to KMT2A leads to transcriptional activation of leukemogenic genes such as <em>HOX</em> and <em>MEIS1</em>. When revumenib is introduced, it fits into the binding pocket of menin and displaces KMT2A. In disrupting the binding interaction, the <em>HOX</em> and <em>MEIS</em> genes are turned off and leukemic cell growth is halted.</p>
<p>View the mechanism of action below:</p>
<div style="padding: 56.25% 0 0 0; position: relative;"><iframe style="position: absolute; top: 0; left: 0; width: 100%; height: 100%;" title="Mechanism of Disease" src="https://player.vimeo.com/video/1004225102?badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479" frameborder="0"></iframe></div>
<p><script src="https://player.vimeo.com/api/player.js"></script></p>
<p>&nbsp;</p>
<hr />
<div style="font-size: small;">
<p><strong>References:</strong></p>
<ol>
<li>Li X, Song Y. J Hematol Oncol. 2021;14:56.</li>
</ol>
</div>


<p>In <em>NPM1m</em> and <em>KMT2Ar</em> acute leukemias, menin interacts with <em>KMT2A</em> and can drive a specific transcription program, leading to leukemogenesis.<sup>1</sup></p>
<p>With a deeper understanding of the mechanisms that contribute to these specific leukemias, menin-KMT2A interactions become an intriguing target to explore.</p>


Menin Inhibitor

Menin-KMT2A Disruption